Lipoprotein (a) level is associated with plaque vulnerability in patients with coronary artery disease: An optical coherence tomography study.
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
15
03
2019
accepted:
05
06
2019
entrez:
28
6
2019
pubmed:
28
6
2019
medline:
28
6
2019
Statut:
epublish
Résumé
High lipoprotein (a) [Lp(a)] levels are an independent factor for worse prognosis in patients with coronary artery disease (CAD). However, the association between serum Lp(a) level and coronary plaque vulnerability remains to be determined. A total of 255 consecutive patients with CAD who underwent optical coherence tomography imaging of culprit lesions were included. Patients were divided into 2 groups according to their Lp(a) levels (the higher Lp(a) group [≥25 mg/dL], The prevalence of thin-cap fibroatheroma (TCFA) was significantly higher in the higher Lp(a) group than in the lower Lp(a) group (23% [ A higher Lp(a) level was associated with a higher frequency of TCFA, particularly in patients with a higher LDL-C level.
Sections du résumé
BACKGROUND
BACKGROUND
High lipoprotein (a) [Lp(a)] levels are an independent factor for worse prognosis in patients with coronary artery disease (CAD). However, the association between serum Lp(a) level and coronary plaque vulnerability remains to be determined.
METHODS
METHODS
A total of 255 consecutive patients with CAD who underwent optical coherence tomography imaging of culprit lesions were included. Patients were divided into 2 groups according to their Lp(a) levels (the higher Lp(a) group [≥25 mg/dL],
RESULTS
RESULTS
The prevalence of thin-cap fibroatheroma (TCFA) was significantly higher in the higher Lp(a) group than in the lower Lp(a) group (23% [
CONCLUSIONS
CONCLUSIONS
A higher Lp(a) level was associated with a higher frequency of TCFA, particularly in patients with a higher LDL-C level.
Identifiants
pubmed: 31245530
doi: 10.1016/j.ijcha.2019.100382
pii: S2352-9067(19)30102-2
pii: 100382
pmc: PMC6582072
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100382Déclaration de conflit d'intérêts
None.
Références
Eur Heart J. 2007 Apr;28(8):961-7
pubmed: 17135281
Lancet. 2018 Oct 13;392(10155):1311-1320
pubmed: 30293769
Circ Cardiovasc Imaging. 2012 Jul;5(4):433-40
pubmed: 22679059
Atherosclerosis. 2016 Mar;246:214-20
pubmed: 26803430
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
Eur Heart J. 2010 Dec;31(23):2844-53
pubmed: 20965889
Eur Heart J. 2011 May;32(10):1251-9
pubmed: 21273202
J Am Coll Cardiol. 2017 Feb 14;69(6):692-711
pubmed: 28183512
Am J Cardiol. 2016 Sep 1;118(5):656-61
pubmed: 27530333
J Am Coll Cardiol. 2012 Mar 20;59(12):1058-72
pubmed: 22421299
Circulation. 1986 Oct;74(4):758-65
pubmed: 2944670
JAMA. 2009 Jul 22;302(4):412-23
pubmed: 19622820
J Am Heart Assoc. 2017 Nov 1;6(11):null
pubmed: 29092845
Atherosclerosis. 2018 Jul;274:16-22
pubmed: 29747086
Circulation. 2019 Mar 19;139(12):1483-1492
pubmed: 30586750
Coron Artery Dis. 2014 Mar;25(2):172-85
pubmed: 24356250
J Clin Lipidol. 2018 Jul - Aug;12(4):1019-1026
pubmed: 29703625
J Am Coll Cardiol. 2018 Jul 17;72(3):287-296
pubmed: 30012322
Am J Cardiol. 2010 Jun 15;105(12):1673-8
pubmed: 20538113
JACC Cardiovasc Interv. 2010 Jul;3(7):766-72
pubmed: 20650439
JAMA. 2009 Jun 10;301(22):2331-9
pubmed: 19509380
Arteriosclerosis. 1988 Nov-Dec;8(6):851-7
pubmed: 2973783
Circulation. 2005 Mar 29;111(12):1551-5
pubmed: 15781733
J Am Coll Cardiol. 2014 May 20;63(19):1982-9
pubmed: 24632281
N Engl J Med. 2009 Dec 24;361(26):2518-28
pubmed: 20032323
J Am Coll Cardiol. 2006 Aug 1;48(3):446-52
pubmed: 16875967